A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Inclusion Criteria:

• Age ≥ 18 years at screening (or ≥ legal age within the country if it is older than 18 years)

• Type 2 diabetes for ≥6 months according to the World Health Organizationclassification

• HbA1c of 7.0% to 10.5%, inclusive, as assessed by the central laboratory

• Treatment of diabetes with diet and exercise alone, or with a stable dose ofmetformin, with or without a sodium-glucose cotransporter-2 inhibitor, for at least 3 months prior to screening

• Body mass index of 23 to 50 kilograms per square meter

Exclusion Criteria:

• Type 1 diabetes

• Use of any glucose-lowering medication, other than metformin with or without asodium-glucose cotransporter-2 inhibitor, within 3 months prior to screening

• Estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 squaremeter, calculated by the Chronic Kidney Disease-Epidemiology equation.

• Uncontrolled and potentially unstable diabetic retinopathy or maculopathy

• History of acute or chronic pancreatitis

• Malignancy within 5 years before screening, except for nonmelanoma skin cancer, insitu carcinoma of the cervix, or in situ prostate cancer

• Myocardial infarction, unstable angina, coronary artery bypass graft surgery orother major cardiovascular surgery, percutaneous coronary intervention, transientischemic attack, cerebrovascular accident, or decompensated congestive heart failurewithin 90 days prior to screening, or currently have New York Heart AssociationClass III or IV heart failure.

• Use of medications that affect glucose control or body weight or history ofbariatric surgery or procedures.